RT Journal Article
SR Electronic
T1 Is Higher Viral Load in SARS-CoV-2 Associated With Death?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.04.20164061
DO 10.1101/2020.08.04.20164061
A1 Klinger Soares Faíco-Filho
A1 Victor Cabelho Passarelli
A1 Nancy Bellei
YR 2020
UL http://medrxiv.org/content/early/2020/08/06/2020.08.04.20164061.abstract
AB Background There is no proven prognostic marker or adequate number of studies in patients hospitalized for coronavirus disease 2019 (COVID-19).Methods We conducted a retrospective cohort study of patients hospitalized with COVID-19 from March 14 to June 17, 2020, at São Paulo Hospital. SARS-CoV-2 viral load was assessed using the cycle threshold (Ct) values obtained from an RT-PCR assay applied to the nasopharyngeal swab samples. Disease severity and patient outcomes were compared.Results Among the 875 patients, 50.1% (439/875) had mild, 30.4% (266/875) moderate, and 19.5% (170/875) severe disease. A Ct value of <25 (472/875) indicated a high viral load, which was independently associated with mortality (OR: 0,34; 95% CI: 0,217–0,533; p < 0.0001).Conclusions Admission SARS-CoV-2 viral load is an important surrogate biomarker of infectivity and is independently associated with mortality among patients hospitalized with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The patients were included in the study after the study was approved by the Ethics Committee of Federal University of Sao Paulo (opinion 4.013.602).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnone